Crescita Therapeutics Inc.

TSX:CTX Stock Report

Market Cap: CA$12.3m

Crescita Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Serge Verreault

Chief executive officer

CA$462.3k

Total compensation

CEO salary percentage81.1%
CEO tenure7.6yrs
CEO ownership3.9%
Management average tenureno data
Board average tenure8.7yrs

Recent management updates

We Think Crescita Therapeutics Inc.'s (TSE:CTX) CEO Compensation Package Needs To Be Put Under A Microscope

May 30
We Think Crescita Therapeutics Inc.'s (TSE:CTX) CEO Compensation Package Needs To Be Put Under A Microscope

Increases to CEO Compensation Might Be Put On Hold For Now at Crescita Therapeutics Inc. (TSE:CTX)

May 05
Increases to CEO Compensation Might Be Put On Hold For Now at Crescita Therapeutics Inc. (TSE:CTX)

Recent updates

Risks To Shareholder Returns Are Elevated At These Prices For Crescita Therapeutics Inc. (TSE:CTX)

Oct 25
Risks To Shareholder Returns Are Elevated At These Prices For Crescita Therapeutics Inc. (TSE:CTX)

We Think Crescita Therapeutics Inc.'s (TSE:CTX) CEO Compensation Package Needs To Be Put Under A Microscope

May 30
We Think Crescita Therapeutics Inc.'s (TSE:CTX) CEO Compensation Package Needs To Be Put Under A Microscope

Why Investors Shouldn't Be Surprised By Crescita Therapeutics Inc.'s (TSE:CTX) 33% Share Price Surge

Jan 04
Why Investors Shouldn't Be Surprised By Crescita Therapeutics Inc.'s (TSE:CTX) 33% Share Price Surge

Is Crescita Therapeutics (TSE:CTX) Using Debt Sensibly?

Nov 18
Is Crescita Therapeutics (TSE:CTX) Using Debt Sensibly?

Increases to CEO Compensation Might Be Put On Hold For Now at Crescita Therapeutics Inc. (TSE:CTX)

May 05
Increases to CEO Compensation Might Be Put On Hold For Now at Crescita Therapeutics Inc. (TSE:CTX)

Crescita Therapeutics Inc.'s (TSE:CTX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Feb 10
Crescita Therapeutics Inc.'s (TSE:CTX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

CEO Compensation Analysis

How has Serge Verreault's remuneration changed compared to Crescita Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CA$3m

Jun 30 2024n/an/a

-CA$3m

Mar 31 2024n/an/a

-CA$2m

Dec 31 2023CA$462kCA$375k

-CA$2m

Sep 30 2023n/an/a

-CA$658k

Jun 30 2023n/an/a

CA$819k

Mar 31 2023n/an/a

CA$1m

Dec 31 2022CA$704kCA$375k

CA$862k

Sep 30 2022n/an/a

CA$627k

Jun 30 2022n/an/a

-CA$468k

Mar 31 2022n/an/a

-CA$1m

Dec 31 2021CA$651kCA$375k

-CA$1m

Sep 30 2021n/an/a

-CA$3m

Jun 30 2021n/an/a

CA$2m

Mar 31 2021n/an/a

CA$95k

Dec 31 2020CA$659kCA$338k

CA$37k

Sep 30 2020n/an/a

CA$146k

Jun 30 2020n/an/a

-CA$4m

Mar 31 2020n/an/a

CA$1m

Dec 31 2019CA$823kCA$336k

CA$2m

Sep 30 2019n/an/a

CA$5m

Jun 30 2019n/an/a

CA$6m

Mar 31 2019n/an/a

CA$3m

Dec 31 2018CA$555kCA$287k

CA$2m

Sep 30 2018n/an/a

-CA$9m

Jun 30 2018n/an/a

-CA$10m

Mar 31 2018n/an/a

-CA$9m

Dec 31 2017CA$734kCA$173k

-CA$11m

Compensation vs Market: Serge's total compensation ($USD330.72K) is above average for companies of similar size in the Canadian market ($USD169.13K).

Compensation vs Earnings: Serge's compensation has been consistent with company performance over the past year.

CEO

Serge Verreault

7.6yrs

Tenure

CA$462,268

Compensation

Mr. Serge Verreault, BA, MBA has been the President of Crescita Therapeutics Inc. since April 17, 2017 and its Chief Executive Officer since April 2, 2018 and is Director from June 20, 2023. Mr. Verreault...

Board Members

NamePositionTenureCompensationOwnership
Serge Verreault
President1.4yrsCA$462.27k3.87%
CA$ 474.7k
Anthony Dobranowski
Independent Director8.7yrsCA$74.75k0.52%
CA$ 64.0k
John London
Independent Vice Chairman8.7yrsCA$60.75k1.01%
CA$ 123.9k
Daniel Chicoine
Non-Executive Chairman8.7yrsCA$72.25k5.51%
CA$ 676.7k
Deborah Shannon-Trudeau
Independent Non-Executive Director3yrsCA$56.75kno data

8.7yrs

Average Tenure

Experienced Board: CTX's board of directors are considered experienced (8.7 years average tenure).